Actinium Pharmaceuticals, Inc. (API) is a clinical-stage, private biotechnology company with:

- Two clinical stage products, Actimab-A and Iomab-B, in development for blood borne cancers.  
- Proprietary technology platform for novel radioimmunotherapy cancer treatments (alpha particles immunotherapy, APIT).
- Proprietary technology platform for manufacturing of the alpha particle emitting radioactive isotope actinium 225 (Ac-225).
- Preclinical data in additional cancer indications.  

The Company’s product candidates are based on its patented APIT technology and other related targeted payload technologies.   APIT technology has been co-developed with Memorial Sloan Kettering Cancer Center (MSKCC) to combine the cancer targeting precision of monoclonal antibodies (mAb) for targeting specific types of cells with the power of alpha emitting radioisotopes, the most potent cancer killing agents in existence.  API’s first APIT drug for the treatment of acute myeloid leukemia (AML) has been administered to 49 patients with promising results and the second generation drug candidate is currently in clinical trials with 18 patients treated to date.   In addition to leukemia drugs, API’s technology has been used to produce drug candidates for treatment of metastatic colorectal and prostate cancers, antiangiogenesis (prevention of blood supply to and growth of many solid cancers) and bone marrow ablation, part of a curative treatment for leukemias, lymphomas and multiple myeloma.

Company’s second clinical stage product Iomab-B is based on another antibody useful in preparation for a hematopoetic stem cell transplantation.  Iomab-B, antibody labeled with iodine 131 (I-131), has demonstrated utility in a number of patient populations and API intends to develop it in a regulatory approval trial while at the same time preparing an APIT based second generation product to follow.

Company plans to develop its products through Phase II clinical trials or in the case of Iomab-B into a pivotal trial, and then partner each drug for completion of development and commercialization with an appropriate third party.  API expects that its revenues will be derived from upfront payments, milestone payments and royalty payments, which payments comprise a standard structure of such partnering deals.  In some markets, API may seek to retain commercial rights and derive additional revenue from sales of its products.

API'S largest shareholder is an affiliate of Memorial Sloan Kettering Cancer Center.